These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38776682)

  • 1. A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding.
    Zuo D; Zhu Y; Wang K; Qin Y; Su Y; Lan S; Li Y; Dong S; Liang Y; Feng M
    Biomed Pharmacother; 2024 Jun; 175():116782. PubMed ID: 38776682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition.
    Ming Q; Celias DP; Wu C; Cole AR; Singh S; Mason C; Dong S; Tran TH; Amarasinghe GK; Ruffell B; Luca VC
    Nat Immunol; 2022 Jul; 23(7):1031-1041. PubMed ID: 35761082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy.
    Mariuzza RA; Shahid S; Karade SS
    J Biol Chem; 2024 May; 300(5):107241. PubMed ID: 38556085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
    Wang J; Sanmamed MF; Datar I; Su TT; Ji L; Sun J; Chen L; Chen Y; Zhu G; Yin W; Zheng L; Zhou T; Badri T; Yao S; Zhu S; Boto A; Sznol M; Melero I; Vignali DAA; Schalper K; Chen L
    Cell; 2019 Jan; 176(1-2):334-347.e12. PubMed ID: 30580966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer.
    Shi AP; Tang XY; Xiong YL; Zheng KF; Liu YJ; Shi XG; Lv Y; Jiang T; Ma N; Zhao JB
    Front Immunol; 2021; 12():785091. PubMed ID: 35111155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia.
    Shapiro M; Herishanu Y; Katz BZ; Dezorella N; Sun C; Kay S; Polliack A; Avivi I; Wiestner A; Perry C
    Haematologica; 2017 May; 102(5):874-882. PubMed ID: 28154084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of USP7 enhances CD8
    Sun LL; Zhao LN; Sun J; Yuan HF; Wang YF; Hou CY; Lv P; Zhang HH; Yang G; Zhang NN; Zhang XD; Lu W
    Acta Pharmacol Sin; 2024 Aug; 45(8):1686-1700. PubMed ID: 38589688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ligand-dependent suppression of TCR signaling by the immune checkpoint receptor LAG3 depends on the cytoplasmic RRFSALE motif.
    Aigner-Radakovics K; De Sousa Linhares A; Salzer B; Lehner M; Izadi S; Castilho A; Pickl WF; Leitner J; Steinberger P
    Sci Signal; 2023 Oct; 16(805):eadg2610. PubMed ID: 37788323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity.
    Maruhashi T; Sugiura D; Okazaki IM; Shimizu K; Maeda TK; Ikubo J; Yoshikawa H; Maenaka K; Ishimaru N; Kosako H; Takemoto T; Okazaki T
    Immunity; 2022 May; 55(5):912-924.e8. PubMed ID: 35413245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
    Qian W; Zhao M; Wang R; Li H
    J Hematol Oncol; 2021 Sep; 14(1):147. PubMed ID: 34526102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte-derived FGL1 accelerates liver metastasis and tumor growth by inhibiting CD8+ T and NK cells.
    Xi F; Sun H; Peng H; Lian Z; Wei H; Tian Z; Sun R; Chen Y
    JCI Insight; 2024 May; 9(13):. PubMed ID: 38973608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.
    Johnson DB; Nixon MJ; Wang Y; Wang DY; Castellanos E; Estrada MV; Ericsson-Gonzalez PI; Cote CH; Salgado R; Sanchez V; Dean PT; Opalenik SR; Schreeder DM; Rimm DL; Kim JY; Bordeaux J; Loi S; Horn L; Sanders ME; Ferrell PB; Xu Y; Sosman JA; Davis RS; Balko JM
    JCI Insight; 2018 Dec; 3(24):. PubMed ID: 30568030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxysophocarpine suppresses hepatocellular carcinoma growth and sensitizes the therapeutic blockade of anti-Lag-3 via reducing FGL1 expression.
    Wang J; Wei W; Tang Q; Lu L; Luo Z; Li W; Lu Y; Pu J
    Cancer Med; 2020 Oct; 9(19):7125-7136. PubMed ID: 32810392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human
    Burova E; Hermann A; Dai J; Ullman E; Halasz G; Potocky T; Hong S; Liu M; Allbritton O; Woodruff A; Pei J; Rafique A; Poueymirou W; Martin J; MacDonald D; Olson WC; Murphy A; Ioffe E; Thurston G; Mohrs M
    Mol Cancer Ther; 2019 Nov; 18(11):2051-2062. PubMed ID: 31395688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinogen-like protein 1 promotes liver-resident memory T-cell exhaustion in hepatocellular carcinoma.
    Yang C; Qian Q; Zhao Y; Huang B; Chen R; Gong Q; Ji H; Wang C; Xia L; You Z; Zhang J; Chen X
    Front Immunol; 2023; 14():1112672. PubMed ID: 36993960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.